{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T23:35:33Z","timestamp":1794612933434,"version":"4.9.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T00:00:00Z","timestamp":1669766400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T00:00:00Z","timestamp":1669766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Antimicrob Resist Infect Control"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Historically, multi-drug resistant organisms have been associated with the ICU setting. The present study sought to define the frequency of isolation from ICU versus non-ICU, phenotypic and genotypic profiles of carbapenem-resistant <jats:italic>Pseudomonas aeruginosa<\/jats:italic> (CR-PA) from a global cohort.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Multicenter surveillance study (17 centers from 12 countries) including 672 CR-PA isolates from 2019 to 2021. Phenotypic carbapenemase testing was assessed. Genotypic carbapenemase testing was conducted (CarbaR and CarbaR NxG) to detect \u03b2-lactamases. Broth microdilution MICs were established for ceftazidime, cefepime, ceftolozane\/tazobactam, and ceftazidime\/avibactam.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>59% of CR-PA were isolated from patients outside the ICU. The most common source in ICU and non-ICU patients was respiratory (55% and 30%, respectively). In the ICU, 35% of isolates were phenotypically carbapenemase-positive versus 29% for non-ICU. VIM was the most common carbapenemase (54% and 44%, respectively) followed by GES (27% and 28%, respectively). Susceptibility to ceftazidime or cefepime were relatively low in ICU (39% and 41% of isolates, respectively) and non-ICU (47% and 52% of isolates, respectively). Ceftolozane\/tazobactam and ceftazidime\/avibactam were more active with 56% and 66% of isolates susceptible in the ICU while 65% and 76% in non-ICU, respectively. When carbapenemase-negative, 86% and 88% of ICU isolates were susceptible to ceftolozane\/tazobactam and ceftazidime\/avibactam. Similarly, in the carbapenemase-negative, non-ICU isolates 88% and 92% of isolates were susceptible, respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Although multidrug resistant pathogens are often regarded as a challenge in the ICU population, the majority of CR-PA were isolated from non-ICU patients. Implementing phenotypic\/genotypic testing will assist in guiding treatment. Carbapenem-resistance in <jats:italic>P. aeruginosa<\/jats:italic> should be regarded as a surrogate for MDR and this phenotype is increasingly prevalent outside the ICU.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13756-022-01187-8","type":"journal-article","created":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T10:05:18Z","timestamp":1669802718000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Carbapenem-resistant Pseudomonas aeruginosa: an assessment of frequency of isolation from ICU versus non-ICU, phenotypic and genotypic profiles in a multinational population of hospitalized patients"],"prefix":"10.1186","volume":"11","author":[{"given":"Christian M.","family":"Gill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Nicolau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the ERACE-PA Global Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,30]]},"reference":[{"key":"1187_CR1","doi-asserted-by":"publisher","first-page":"e183927","DOI":"10.1001\/jamanetworkopen.2018.3927","volume":"1","author":"SY Tartof","year":"2018","unstructured":"Tartof SY, Kuntz JL, Chen LH, Wei R, Puzniak L, Tian Y, et al. Development and assessment of risk scores for carbapenem and extensive \u03b2-Lactam resistance among adult hospitalized patients with Pseudomonas aeruginosa infection. JAMA Netw Open. 2018;1:e183927. https:\/\/doi.org\/10.1001\/jamanetworkopen.2018.3927.","journal-title":"JAMA Netw Open"},{"key":"1187_CR2","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1097\/CCM.0b013e31823bc8d0","volume":"40","author":"KJ Eagye","year":"2012","unstructured":"Eagye KJ, Banevicius MA, Nicolau DP. Pseudomonas aeruginosa is not just in the intensive care unit any more: implications for empirical therapy. Crit Care Med. 2012;40:1329\u201332. https:\/\/doi.org\/10.1097\/CCM.0b013e31823bc8d0.","journal-title":"Crit Care Med"},{"key":"1187_CR3","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1007\/s10096-021-04308-0","volume":"40","author":"CM Gill","year":"2021","unstructured":"Gill CM, Akta\u015f E, Alfouzan W, Bourassa L, Brink A, Burnham CD, et al. The ERACE-PA global surveillance program: Ceftolozane\/tazobactam and Ceftazidime\/avibactam in vitro activity against a Global Collection of Carbapenem-resistant Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis. 2021;40:2533\u201341. https:\/\/doi.org\/10.1007\/s10096-021-04308-0.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"1187_CR4","unstructured":"CLSI. Performance Standards for Antimicrobial Susceptibility Testing\u2014Thirty-first Edition: M100. 2021."},{"key":"1187_CR5","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1093\/cid\/ciw353","volume":"63","author":"AC Kalil","year":"2016","unstructured":"Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al. Management of adults with hospital-acquired and ventilator-associated Pneumonia: 2016 clinical practice guidelines by the infectious Diseases Society of America and the american thoracic society. Clin Infect Dis. 2016;63:e61-111. https:\/\/doi.org\/10.1093\/cid\/ciw353.","journal-title":"Clin Infect Dis"},{"key":"1187_CR6","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1093\/infdis\/jiy578","volume":"219","author":"GH Talbot","year":"2019","unstructured":"Talbot GH, Das A, Cush S, Dane A, Wible M, Echols R, et al. Evidence-based study design for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. J Infect Dis. 2019;219:1536\u201344. https:\/\/doi.org\/10.1093\/infdis\/jiy578.","journal-title":"J Infect Dis"},{"key":"1187_CR7","doi-asserted-by":"publisher","first-page":"e0667","DOI":"10.1097\/CCE.0000000000000667","volume":"4","author":"MD Zilberberg","year":"2022","unstructured":"Zilberberg MD, Nathanson BH, Puzniak LA, Zilberberg NWD, Shorr AF. Inappropriate empiric therapy impacts complications and hospital resource utilization differentially among different types of bacterial nosocomial pneumonia: a cohort study, United States, 2014\u20132019. Crit Care Explor. 2022;4:e0667. https:\/\/doi.org\/10.1097\/CCE.0000000000000667.","journal-title":"Crit Care Explor"},{"key":"1187_CR8","doi-asserted-by":"publisher","first-page":"dlab187","DOI":"10.1093\/jacamr\/dlab187","volume":"3","author":"J Howard-Anderson","year":"2021","unstructured":"Howard-Anderson J, Bower CW, Smith G, Satola SW, Jacob JT. Mortality in patients with carbapenem-resistant Pseudomonas aeruginosa with and without susceptibility to traditional antipseudomonal \u03b2-lactams. JAC Antimicrob Resist. 2021;3:dlab187. https:\/\/doi.org\/10.1093\/jacamr\/dlab187.","journal-title":"JAC Antimicrob Resist"},{"key":"1187_CR9","doi-asserted-by":"publisher","first-page":"e0120421","DOI":"10.1128\/AAC.01204-21","volume":"65","author":"CM Gill","year":"2021","unstructured":"Gill CM, Akta\u015f E, Alfouzan W, Bourassa L, Brink A, Burnham CD, et al. Elevated MICs of susceptible antipseudomonal cephalosporins in non-carbapenemase-producing, carbapenem-resistant Pseudomonas aeruginosa: implications for dose optimization. Antimicrob Agents Chemother. 2021;65:e0120421. https:\/\/doi.org\/10.1128\/AAC.01204-21.","journal-title":"Antimicrob Agents Chemother"},{"key":"1187_CR10","doi-asserted-by":"publisher","first-page":"ofab320","DOI":"10.1093\/ofid\/ofab320","volume":"8","author":"SH Lob","year":"2021","unstructured":"Lob SH, DePestel DD, DeRyke CA, Kazmierczak KM, Young K, Motyl MR, et al. Ceftolozane\/Tazobactam and Imipenem\/Relebactam cross-susceptibility among clinical Isolates of Pseudomonas aeruginosa from patients with respiratory tract infections in ICU and Non-ICU Wards-SMART United States 2017\u20132019. Open Forum Infect Dis. 2021;8:ofab320. https:\/\/doi.org\/10.1093\/ofid\/ofab320.","journal-title":"Open Forum Infect Dis"},{"key":"1187_CR11","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1080\/22221751.2022.2048972","volume":"11","author":"FC Tenover","year":"2022","unstructured":"Tenover FC, Nicolau DP, Gill CM. Carbapenemase-producing Pseudomonas aeruginosa -an emerging challenge. Emerg Microbes Infect. 2022;11:811\u20134. https:\/\/doi.org\/10.1080\/22221751.2022.2048972.","journal-title":"Emerg Microbes Infect"},{"key":"1187_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2022.115731","author":"K Hernado","year":"2022","unstructured":"Hernado K, Waite L, Bairagdar N, Manigaba K, Teelucksingh K, Dunn R, et al. A waterfall of susceptibility results: impact of microbiology testing cascade for MDROs. Diagn Microbiol Infect Dis. 2022. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2022.115731 Epub ahead of print.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"1187_CR13","doi-asserted-by":"publisher","first-page":"e01140-18","DOI":"10.1128\/JCM.01140-18","volume":"56","author":"PD Tamma","year":"2018","unstructured":"Tamma PD, Simner PJ. Phenotypic detection of carbapenemase-producing organisms from clinical isolates. J Clin Microbiol. 2018;56:e01140-18. https:\/\/doi.org\/10.1128\/JCM.01140-18.","journal-title":"J Clin Microbiol"},{"issue":"9","key":"1187_CR14","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.2174\/1389450117666160310144501","volume":"17","author":"T Naas","year":"2016","unstructured":"Naas T, Dortet L, Iorga BI. Structural and functional aspects of class A Carbapenemases. Curr Drug Targets. 2016;17(9):1006\u201328.","journal-title":"Curr Drug Targets"},{"key":"1187_CR15","doi-asserted-by":"crossref","unstructured":"Poirel L, Ortiz De La Rosa JM, Kieffer N, Dubois V, Jayol A, Nordmann P. Acquisition of extended-spectrum \u03b2-Lactamase GES-6 leading to resistance to ceftolozane-tazobactam combination in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2018;63:e01809\u201318.","DOI":"10.1128\/AAC.01809-18"}],"container-title":["Antimicrobial Resistance &amp; Infection Control"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13756-022-01187-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13756-022-01187-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13756-022-01187-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T10:07:19Z","timestamp":1669802839000},"score":1,"resource":{"primary":{"URL":"https:\/\/aricjournal.biomedcentral.com\/articles\/10.1186\/s13756-022-01187-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,30]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1187"],"URL":"https:\/\/doi.org\/10.1186\/s13756-022-01187-8","relation":{},"ISSN":["2047-2994"],"issn-type":[{"value":"2047-2994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,30]]},"assertion":[{"value":"27 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was determined to be exempted as not constituting research involving human subjects by the Hartford Hospital IRB (Assurance #FWA00021932) and thus informed consent waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CMG has received research grants from Cepheid, Everest Medicines, and Shionogi. DPN is a consultant, speaker bureau member and\/or has received other research grants from Abbvie, Cepheid, Merck, Paratek, Pfizer, Wockhardt, and Shionogi.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"146"}}